Patients ( n = @ ) with very high CVD risk and LDL-C levels of @ mg/dL or greater or high CVD risk and LDL-C of @ mg/dL or greater on baseline atorvastatin @ or @ mg were randomized to one of the following : @ ) add-on alirocumab @ mg every @ weeks ( Q@W ) sc ; @ ) add-on ezetimibe @ mg/d ; @ ) double atorvastatin dose ; or @ ) for atorvastatin @ mg regimen only , switch to rosuvastatin @ mg .